Antineoplastic Agents TRIZ Cases

Zebrafish microRNA composition reprograms cancer cells to a normal phenotype, addressing the limitation of conventional treatments that damage healthy tissue.

Combining selective SCD1 inhibitors with tyrosine kinase inhibitors targets hepatocellular carcinoma through dual-mechanism action.

Targeting the HIF-2α PAS-B cavity disrupts dimerization with HIF1β, resolving specificity issues against HIF1α.

A memetic optimization algorithm determines beam geometry and dosimetric parameters to generate radiation therapy treatment plans.

Merging amcenestrant and ribociclib overcomes limited anti-tumor efficacy of single agents by inducing significant tumor stasis.

Addresses acquired resistance in EGFR-mutant cancers by merging SHP2 inhibition with EGFR blockade to sustain ERK suppression.

HNF4-α antagonist binds ligand binding domain to inhibit transcriptional activity, reducing Wnt5a expression and gastric cancer cell growth.

Combining zanubrutinib with moderate CYP3A inducers reduces atrial fibrillation rates and extends progression-free survival in B-cell proliferative disorders.

Amcenestrant replaces intramuscular injections with oral dosing to achieve sustained plasma concentrations and effective estrogen receptor degradation.

Targeting serine 2152 phosphorylated filamin A normalizes PI3K/Akt signaling, resolving specificity issues in kinase inhibitor therapies.

A pyridopyrimidinone compound inhibits PI3K activity to enable combination therapy with chemotherapeutic agents.

Chlorin e6 anhydride purification reduces di-L-aspartyl chlorin e6 precursors in Talaporfin Sodium synthesis.

Imeglimin enhances antitumor efficacy while reducing sorafenib toxicity through synergistic AMPK activation and mTOR inhibition.

Combining EGFR inhibitors with PERK activators overcomes resistance mechanisms and extends response duration in mutant cancers.

ANRIL-TDO double-stranded DNA polynucleotide blocks triplex formation with genomic DNA to modulate gene regulatory activity.

Dual inhibition of BET and PARP enzymes overcomes drug resistance in platinum-responsive pancreatic cancer patients.

A traditional Chinese medicine composition reduces tumor volume and enhances immune function through specific herbal blends.

Combining CDK and bromodomain inhibitors targets super-enhancers to reduce oncogenic gene expression in cancer.

A polyenylpyrrole derivative inhibits oral cancer cell proliferation and migration by modulating Par-4 and IL-17RA expression levels.

SARD ligands degrade androgen receptor splice variants lacking the ligand binding domain, overcoming resistance in castration-resistant prostate cancer.

Combining an MDM2 inhibitor with a CK1α degrading agent restores p53 activity in wild type tumors.

Applying a polymer matrix with beta emitters delivers localized radiation to skin tumors while sparing deeper healthy tissues.

Co-administering CDK 4/6 inhibitors and mtRTKIs controls tumor growth while reducing toxicity associated with traditional chemotherapies.

Anaerobic alcohol dehydrogenase promoter directs high-level gene expression to hypoxic tumors, avoiding normal tissue toxicity.

Formula I compound derived from Mesembryanthemum crystallinum L. induces apoptosis in malignant melanoma cells.

Combines lenvatinib, ifosfamide, and etoposide to deliver enhanced antitumor effects across multiple tumor types.

Desloratadine improves prognosis by targeting cellular proliferation, overcoming limited effectiveness of conventional therapies.

Salsolinol composition inhibits STAT3 and AKT phosphorylation, reducing tumor-related gene expression to treat liver cancer.

A guide RNA molecule directs Cas9 protein to inhibit TCOF1 gene expression in cancer cells.

Cinnamomum zeylanicum essential oil selectively inhibits metastatic melanoma cells through oxidative stress induction and mitochondrial damage.

Lysosomal acid lipase replacement therapy combined with pyruvate dehydrogenase inhibition modulates tumor microenvironments.

Reverse transcriptase inhibitors suppress LINE-1 retrotransposition, reducing genomic instability and drug resistance in tumors.

Co-administering eribulin and lenvatinib overcomes single-agent limitations by synergistically reducing tumor volume and extending survival.

Voacangine resolves the trade-off between angiogenesis inhibition effectiveness and cytotoxicity by targeting VEGF expression without harming healthy cells.

Small interfering RNAs degrade mRNA encoding androgen receptor coregulators to inhibit signaling pathways in aggressive prostate cancer cells.

Pairing Bcl-2 family inhibitors with aurora kinase inhibitors overcomes resistance and reduces toxicity in breast, ovarian, pancreatic, or prostate cancer.

Combining OPC31260 and OPC41061 resolves mixed treatment reliability by inducing apoptosis and reducing angiogenesis in clear cell renal carcinoma.

Lanthanide oxide nanoparticles concentrate in tumors to boost radiation absorption while reducing toxicity to healthy tissue.

DOT1L inhibitor compound selectively targets MLL-rearranged leukemia cells, reducing tumor size while minimizing toxicity to normal tissues.

Silencing PDZ-RHOGEF via small hairpin RNA sensitizes glioblastoma cells, overcoming treatment resistance and reducing invasive cell dispersion.

Nitroxoline replaces surgical excision with pharmacological treatment to eliminate cutaneous neurofibromas while avoiding regrowth, scarring, and high costs.

A composite herbal extract arrests cell cycle progression and reduces cancer stem cell populations.

Blocking leukotriene synthesis inhibits Nestin expression, sparing healthy cells from Shh inhibitor toxicity.

Antisense oligonucleotides targeting SMAD7 block TGF-beta signaling to treat colorectal cancer.

Administering ET-743 alongside PARP-1 inhibitors overcomes limited single-agent efficacy by blocking DNA repair pathways to maximize tumor cell destruction.

Combining HIF-2α inhibitors with immunotherapeutic agents targets cancer cells through synergistic biological pathways.

Specific thiosemicarbazone compounds block MDR1 efflux pumps, restoring chemotherapeutic sensitivity in multidrug-resistant cancer cells.

Locked nucleic acid oligonucleotides enhance binding affinity and cellular uptake to overcome bioavailability limits in cancer therapy.